Literature DB >> 26662105

In search of underlying mechanisms and potential drugs of melphalan-induced vascular toxicity through retinal endothelial cells using bioinformatics approach.

Yang Yang1, Yiqiao Xing1, Chaoqun Liang1, Liya Hu2, Fei Xu2, Qi Mei3.   

Abstract

We aimed to explore molecular mechanism and drug candidates of vascular toxicities associated with melphalan after treating human retinal endothelial cells (RECs). GSE34381 microarray data was firstly downloaded and used to identify the differentially expressed genes (DEGs) in human REC treated with melphalan vs. untreated cells by limma package in R language. The transcription network was constructed based on TRANSFAC database and the top five transcription factors (TFs) were select with a measure of regulatory impact factor, followed by the construction of function modules. Gene ontology enrichment analyses were performed to explore the enriched functions. Connectivity Map analysis was conducted to predict the potential drugs overcoming the melphalan's actions on REC. Totally, 75 DEGs were identified, including 70 up-regulated and five down-regulated genes. Transcription network with 1311 nodes and 1875 edges was constructed and the top five TFs were CREM, MYC, FLI1, NF-κB1, and JUN. Functional modules indicated that NF-κB1 and MYC were the important nodes. The upregulated genes as well as the genes involved in the modules mainly participated in biological process of immune response, cell proliferation, and cell motion. Five small molecules were predicted to be potential drug candidates, including doxorubicin, fipexide, daunorubicin, tiabendazole, and GW-8510. Based on these results, we speculate that NF-κB1 and MYC might involve in the molecular mechanism of vascular toxicity induced by melphalan through regulating their target genes. Five small molecules might be drug candidates to overcome the melphalan-induced vascular toxicity via targeting to MYC and JUN.

Entities:  

Keywords:  Connectivity Map analysis; Melphalan; Retinoblastoma; Transcription factor; Transcription network

Mesh:

Substances:

Year:  2015        PMID: 26662105     DOI: 10.1007/s13277-015-4444-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  48 in total

1.  The treatment of retinoblastoma by x-ray and triethylene melamine.

Authors:  A B REESE; G A HYMAN; N D TAPLEY; A W FORREST
Journal:  AMA Arch Ophthalmol       Date:  1958-11

2.  Intra-ophthalmic artery chemotherapy triggers vascular toxicity through endothelial cell inflammation and leukostasis.

Authors:  Jena J Steinle; Qiuhua Zhang; Karin Emmons Thompson; Jordan Toutounchian; C Ryan Yates; Carl Soderland; Fan Wang; Clinton F Stewart; Barrett G Haik; J Scott Williams; J Scott Jackson; Timothy D Mandrell; Dianna Johnson; Matthew W Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-30       Impact factor: 4.799

3.  Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications.

Authors:  Carol L Shields; Carlos G Bianciotto; Pascal Jabbour; Gregory C Griffin; Aparna Ramasubramanian; Robert Rosenwasser; Jerry A Shields
Journal:  Arch Ophthalmol       Date:  2011-06-13

Review 4.  Current update on retinoblastoma.

Authors:  Samuel K Houston; Timothy G Murray; Stacey Quintero Wolfe; Cristina E Fernandes
Journal:  Int Ophthalmol Clin       Date:  2011

Review 5.  Vascular toxicity associated with chemotherapy and hormonotherapy.

Authors:  D C Doll; J W Yarbro
Journal:  Curr Opin Oncol       Date:  1994-07       Impact factor: 3.645

Review 6.  Role of autophagy in cancer.

Authors:  Robin Mathew; Vassiliki Karantza-Wadsworth; Eileen White
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

Review 7.  Retinoblastoma: review of current management.

Authors:  Murali Chintagumpala; Patricia Chevez-Barrios; Evelyn A Paysse; Sharon E Plon; Richard Hurwitz
Journal:  Oncologist       Date:  2007-10

Review 8.  Nuclear factor-kappa B and cancer: its role in prevention and therapy.

Authors:  Alok C Bharti; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

9.  Microarray analysis after RNA amplification can detect pronounced differences in gene expression using limma.

Authors:  Ilhem Diboun; Lorenz Wernisch; Christine Anne Orengo; Martin Koltzenburg
Journal:  BMC Genomics       Date:  2006-10-09       Impact factor: 3.969

10.  Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2).

Authors:  Per Fogelstrand; Chloé C Féral; Ramin Zargham; Mark H Ginsberg
Journal:  J Exp Med       Date:  2009-10-19       Impact factor: 14.307

View more
  4 in total

1.  Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.

Authors:  Arjen Gebraad; Roope Ohlsbom; Juho J Miettinen; Promise Emeh; Toni-Karri Pakarinen; Mikko Manninen; Antti Eskelinen; Kirsi Kuismanen; Ana Slipicevic; Fredrik Lehmann; Nina N Nupponen; Caroline A Heckman; Susanna Miettinen
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

Review 2.  Developments in toxicogenomics: understanding and predicting compound-induced toxicity from gene expression data.

Authors:  Benjamin Alexander-Dann; Lavinia Lorena Pruteanu; Erin Oerton; Nitin Sharma; Ioana Berindan-Neagoe; Dezső Módos; Andreas Bender
Journal:  Mol Omics       Date:  2018-08-06

3.  Enhanced identification of significant regulators of gene expression.

Authors:  Rezvan Ehsani; Finn Drabløs
Journal:  BMC Bioinformatics       Date:  2020-04-06       Impact factor: 3.169

4.  Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells.

Authors:  Ursula Winter; Hebe A Mena; Soledad Negrotto; Eloisa Arana; Guillem Pascual-Pasto; Viviana Laurent; Mariona Suñol; Guillermo L Chantada; Angel M Carcaboso; Paula Schaiquevich
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.